Skip to main content
. 2021 Sep 7;15:3787–3795. doi: 10.2147/OPTH.S328160

Figure 1.

Figure 1

Representative case of a treatment-naïve nAMD showing complete resolution of subretinal fluid along with significant reduction in the subretinal hyperreflective material (SHRM) at weeks 4 (B), 8 (C), and 12 (D) as compared to the baseline (A) after a single dose of intravitreal brolucizumab injection.